Table 7.
Broad spectrum anti-RNA virus activities of Ti and V substituted polyoxotungstates
| Compound | EC50 (μM) a |
|||||
|---|---|---|---|---|---|---|
| DFV b | FluV A b | RSV b | PfluV 2 b | CDV c | HIV-1 b | |
| PM-43 | 10.7 ± 6.7 | 8.4 ± 6.5 | 1.6 d | > 100 | 7.5 ± 1.0 | 0.3 ± 0.12 |
| PM-47 | 10.5 ± 6.9 | 11.5 ± 0.6 | 29.0 d | 67.1 d | 6.0 ± 0.6 | 0.03 ± 0.01 |
| PM-518 | 36.8 ± 3.0 | 62 ± 27 | 26.5 d | 53 ± 39 | > 50 | 2.0 ± 0.8 |
| PM-520 | 11.7 ± 7.1 | 45 ± 26 | 0.74 ± 0.6 | 23 ± 2.4 | 7.4 ± 0.4 | 2.0 ± 0.5 |
| PM-523 | > 61.5 | 5.6 ± 2.0 | 1.3 ± 0.5 | 2.5 ± 1.3 | 7.3 ± 1.1 | 0.3 ± 0.1 |
| PM-1001 | 0.45 ± 0..1 | 1.75 ± 1.6 | < 0.16 | 1.1 ± 0.9 | 5.7 ± 0.5 | 0.14 ± 0.17 |
| PM-1002 | 2.0 ± 1.4 | 4.0 ± 1.7 | 0.75 ± 0.05 | 0.75 ± 0.05 | 2.8 ± 1.0 | 0.03 ± 0.01 |
| Ribavirin | > 100 | 5.0 ± 2.8 | 3.9 ± 3.1 | 14.0 ± 4.8 | 74 ± 35 | Nd e |
a
Average values for three to seven independent experiments.
b
EC50 was determined by MTT method.
c
EC50 was determined by plaque reduction method.
d
Average of two experiments.
e
Not determined.